[go: up one dir, main page]

AU2015292212B2 - Solid oral formulation of fenretinide - Google Patents

Solid oral formulation of fenretinide Download PDF

Info

Publication number
AU2015292212B2
AU2015292212B2 AU2015292212A AU2015292212A AU2015292212B2 AU 2015292212 B2 AU2015292212 B2 AU 2015292212B2 AU 2015292212 A AU2015292212 A AU 2015292212A AU 2015292212 A AU2015292212 A AU 2015292212A AU 2015292212 B2 AU2015292212 B2 AU 2015292212B2
Authority
AU
Australia
Prior art keywords
fenretinide
solid dispersion
amorphous solid
disease
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015292212A
Other languages
English (en)
Other versions
AU2015292212A1 (en
Inventor
Aimesther BETANCOURT
Marc Lemieux
Roch Thibert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laurent Pharmaceuticals
Original Assignee
Laurent Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurent Pharmaceuticals filed Critical Laurent Pharmaceuticals
Publication of AU2015292212A1 publication Critical patent/AU2015292212A1/en
Application granted granted Critical
Publication of AU2015292212B2 publication Critical patent/AU2015292212B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
AU2015292212A 2014-07-25 2015-07-24 Solid oral formulation of fenretinide Active AU2015292212B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462029119P 2014-07-25 2014-07-25
US62/029,119 2014-07-25
PCT/CA2015/000445 WO2016011535A1 (fr) 2014-07-25 2015-07-24 Formulation orale solide de fenrétinide

Publications (2)

Publication Number Publication Date
AU2015292212A1 AU2015292212A1 (en) 2017-03-02
AU2015292212B2 true AU2015292212B2 (en) 2019-03-14

Family

ID=55162354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015292212A Active AU2015292212B2 (en) 2014-07-25 2015-07-24 Solid oral formulation of fenretinide

Country Status (6)

Country Link
US (1) US10512619B2 (fr)
EP (1) EP3171860B1 (fr)
JP (1) JP6649378B2 (fr)
AU (1) AU2015292212B2 (fr)
CA (1) CA2966517C (fr)
WO (1) WO2016011535A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011533PA (en) 2013-04-16 2021-01-28 Univ Monash Method of Viral Inhibition
CA2966517C (fr) 2014-07-25 2021-03-16 Laurent Pharmaceuticals Formulation orale solide de fenretinide
AR104691A1 (es) * 2016-05-18 2017-08-09 Labyes De Uruguay S A Composición veterinaria de imidacloprid, moxidectina y praziquantel de administración tópica cutánea (spot on) para tratamiento y prevención de las ecto y endoparasitosis que afectan a los perros
US11510945B2 (en) 2018-04-16 2022-11-29 The Royal Institution For Advancement Of Learning/Mcgill University Compositions and methods for enhancing ion transporter activity and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009016663A1 (fr) * 2007-07-31 2009-02-05 Istituto Giannina Gaslini Conjugués de dextrine amphiphiles et leur utilisation dans des formulations pharmaceutiques en tant qu'agents complexants pour des médicaments hydrophobes pour améliorer la solubilité aqueuse et par conséquent l'efficacité thérapeutique de médicaments complexés
US20120093718A1 (en) * 2006-03-29 2012-04-19 Scitech Development, Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
EP0671953A4 (fr) 1992-11-13 1996-01-10 Univ Ohio State Res Found Analogues arylamide de n-(4-hydroxyphenyl)retinamide-o-glucuronide.
JP2000026270A (ja) * 1998-07-09 2000-01-25 Isehan:Kk レチノイド類を含有する皮膚外用剤
WO2002058689A1 (fr) 2000-12-05 2002-08-01 Childrens Hospital Los Angeles Compositions pharmaceutiques de fenretinide presentant une biodisponibilite accrue et leurs procedes d'utilisation
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
EP1469830A2 (fr) 2002-02-01 2004-10-27 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection
WO2005084657A1 (fr) 2004-03-02 2005-09-15 Mcgill University Compositions et methodes pour prevenir ou pour traiter une reaction inflammatoire
WO2005092314A1 (fr) 2004-03-18 2005-10-06 Istituto Nazionale Per Lo Studio E La Cura Del Tum 4-oxo-fenretinide, administre seul et en combinaison avec le fenretinide, comme agent preventif et therapeutique contre le cancer
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
EP1959945B1 (fr) 2005-12-13 2014-12-03 McGill University Fenretinide pour corriger d'un déséquilibre lipidique chez un sujet
WO2007127488A1 (fr) 2006-04-27 2007-11-08 Shenoy Narmada R Compositions et méthodes pour traiter ou prévenir des maladies de voies du corps
WO2007136636A1 (fr) 2006-05-17 2007-11-29 Childrens Hospital Los Angeles Research Institute Association de médicaments pour le traitement de troubles hyperproliférants
JP2008007472A (ja) * 2006-06-30 2008-01-17 Picaso Cosmetic Laboratory Ltd ポリエン構造成分配合剤
WO2008006007A2 (fr) * 2006-07-03 2008-01-10 Columbia University Régulateur de la conductance transmembranaire de la mucoviscidose (cftr) défectueux provoquant une synthèse accrue de sphingolipide
US8642658B2 (en) 2008-02-21 2014-02-04 Royal Institution For The Advancement Of Learning/Mcgill University Treatment of neural diseases or conditions
AT506477B1 (de) 2008-02-21 2010-07-15 Schweighofer Franz Wärmespeichereinrichtung
WO2009106663A1 (fr) * 2008-02-28 2009-09-03 Uvix S.L.L. Procédé amélioré pour l'installation, sur une construction, d'un matériau de placage et élément d'assemblage à sec assurant l'isolation, procédé d'intégration dudit élément
US8460635B2 (en) 2008-03-12 2013-06-11 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
US8088822B2 (en) * 2008-07-08 2012-01-03 Ji Zhang Use of fenretinide or bioactive derivatives thereof and pharmaceutical compositions comprising the same
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
EP2648711A2 (fr) 2010-12-06 2013-10-16 ReVision Therapeutics, Inc. Compositions et méthodes pour le traitement d'affections ophtalmiques
SG10202011533PA (en) 2013-04-16 2021-01-28 Univ Monash Method of Viral Inhibition
CA2966517C (fr) 2014-07-25 2021-03-16 Laurent Pharmaceuticals Formulation orale solide de fenretinide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120093718A1 (en) * 2006-03-29 2012-04-19 Scitech Development, Llc Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery
WO2009016663A1 (fr) * 2007-07-31 2009-02-05 Istituto Giannina Gaslini Conjugués de dextrine amphiphiles et leur utilisation dans des formulations pharmaceutiques en tant qu'agents complexants pour des médicaments hydrophobes pour améliorer la solubilité aqueuse et par conséquent l'efficacité thérapeutique de médicaments complexés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Desai, KGH et al (2011) Pharm Res 28: 2599-2609 *
Falconi, M et al (2014) Journal of Microencapsulation 31: 41-48 *

Also Published As

Publication number Publication date
AU2015292212A1 (en) 2017-03-02
US20190117599A1 (en) 2019-04-25
EP3171860B1 (fr) 2024-12-11
EP3171860A1 (fr) 2017-05-31
JP6649378B2 (ja) 2020-02-19
US10512619B2 (en) 2019-12-24
EP3171860C0 (fr) 2024-12-11
WO2016011535A1 (fr) 2016-01-28
JP2017521501A (ja) 2017-08-03
EP3171860A4 (fr) 2017-08-09
CA2966517C (fr) 2021-03-16
CA2966517A1 (fr) 2016-01-28

Similar Documents

Publication Publication Date Title
US10512619B2 (en) Solid oral formulation of fenretinide
US20110014282A1 (en) Pharmaceutical composition for poorly soluble drugs
US9616025B2 (en) Compressed tablet containing Δ9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
JP2013503166A (ja) 不溶性剤を送達するための組成物
EP3616696B1 (fr) Composition pharmaceutique contenant de l'enzalutamide pouvant être administrée par voie orale
JP2010513356A (ja) ニューロキニンアンタゴニストを含む製剤
TW201311236A (zh) 塞來昔布固體分散體及其製備方法
WO2010111264A2 (fr) Préparations de rasagiline
EP3620156A1 (fr) Composition ayant une solubilité dans l'eau et une biodisponibilité améliorées
JP2024033012A (ja) 医薬組成物
US10406127B2 (en) Solid oral formulation of fenretinide
CA3029543A1 (fr) Composition pharmaceutique a liberation immediate d'agents chelateurs du fer
EP3646867B1 (fr) Composition pharmaceutique
EP3305282A2 (fr) Composition de préparation solide contenant du pranlukast à biodisponibilité améliorée et procédé pour sa préparation
KR20190062260A (ko) 두타스테라이드가 봉입된 나노 가용화 다공체, 이를 포함하는 약학 조성물 및 이의 제조방법
WO2021106004A1 (fr) Composition pharmaceutique de s-adénosylméthionine
US9775832B2 (en) Pharmaceutical composition for oral administration
EP3706731A1 (fr) Formulations améliorées de médicaments
US9408835B2 (en) Pharmaceutical composition for oral administration
KR20250041176A (ko) 나포라페닙을 포함하는 무정형 고체 분산물
WO2024033703A1 (fr) Dispersions solides amorphes comprenant du naporafénib
WO2014016850A1 (fr) Composition pharmaceutique stable de fluindione

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)